CervoMed Inc. will collaborate with the UK EXPERTS-ALS clinical trial platform, sponsored by Sheffield Teaching Hospitals NHS Foundation Trust and funded by the UK NIHR and leading motor neuron disease charities, to evaluate its drug candidate neflamapimod in amyotrophic lateral sclerosis. The randomized, multi-center platform trial will initially enroll about 35 ALS participants to assess neflamapimod’s impact on neurofilament light chain levels, with potential expansion to up to 80 patients. The first ALS patient is expected to be dosed by the end of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9656394-en) on February 18, 2026, and is solely responsible for the information contained therein.